跳到正文
原文
Endpoints News 生物医药· Elizabeth Cairns·· 2026-10-19AI 评分30

吉利德口服 α4β7 抑制剂溃疡性结肠炎 II 期数据:缓解率高于 Entyvio

Gilead’s pill posts stronger colitis remission rates than Entyvio

AI 导读

吉利德口服 α4β7 抑制剂在溃疡性结肠炎 II 期剂量探索试验中,缓解率高于 Entyvio。公司计划明年启动该药的后期临床试验。

正文

Gilead Sci­ences is to start late-stage tri­als of its oral α4β7 in­hibitor in ul­cer­a­tive col­i­tis next year, af­ter da­ta from a Phase 2 dose-find­ing tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news